Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Extends by $1M siRNA-Based Target-Validation Deal With Cystic Fibrosis Foundation

NEW YORK (GenomeWeb News) — Galapagos has extended by 15 months and €800,000 ($1 million) a two-year agreement with Cystic Fibrosis Foundation Therapeutics to use its siRNA and cDNA collections to develop new treatments for cystic fibrosis, the company said today.
 
Galapagos said its BioFocus DPI division is using its SilenceSelect adenoviral library to design assays that can identify and validate potential targets that could be the “basis for the development of new medicines.”   
 
Galapagos signed the original two-year, €1.3-million research agreement with CFFT, a drug development affiliate of the Cystic Fibrosis Foundation, in April 2005.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.